| Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on May 1, 2025, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 3,688 shares of its common stock to five new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock units were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-05-02 21:00:00 |
Czytaj oryginał (ang.) |
| Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results |
On track for six major study readouts across four programs over the next 12 months Ready to initiate pivotal studies in two developmental and epileptic encephalopathy (DEE) programs in mid-year 2025: EMERALD for broad DEEs with relutrigine and EMBRAVE3 for SCN2A GoF with elsunersen Vormatrigine continues to generate a best-in-class safety profile with new data demonstrating no food effect and higher dosing tolerability Praxis to host a virtual investor event on Friday, May 2, 2025 to discuss its DEE portfolio [registration link] Cash and investments of $472 million as of March 31, 2025, maintains runway into 2028 BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the first quarter 2025. “We have made substantial progress in advancing our promising late-stage epilepsy portfolio and are firing on all cylinders through this unpredictable time in the industry,” said Marcio Souza, president and chief executive officer of Praxis. |
globenewswire.com |
2025-05-02 12:30:00 |
Czytaj oryginał (ang.) |
| Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies |
BOSTON, April 08, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be hosting a virtual investor event on Friday, May 2, 2025 from 10:00 a.m. to 11:30 a.m. EDT. |
globenewswire.com |
2025-04-08 12:00:00 |
Czytaj oryginał (ang.) |
| Praxis Precision Medicines to Participate in Upcoming April Conferences |
BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences this April: |
globenewswire.com |
2025-04-03 21:00:00 |
Czytaj oryginał (ang.) |
| Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on April 1, 2025, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 8,763 shares of its common stock to four new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock units were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-04-03 20:00:00 |
Czytaj oryginał (ang.) |
| Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on March 3, 2025, the Compensation Committee of Praxis' Board of Directors granted non-qualified stock option awards to purchase an aggregate of 2,000 shares of its common stock and restricted stock unit awards covering an aggregate of 7,288 shares of its common stock to six new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The stock options and restricted stock units were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-03-04 19:00:00 |
Czytaj oryginał (ang.) |
| Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade) |
Ulixacaltamide's Phase 3 study was recommended to stop for futility, significantly lowering its chances of success in essential tremor. Investor focus shifts to the epilepsy pipeline, led by vormatrigine (focal epilepsy) and relutrigine (SCN2A/SCN8A-DEEs). Vormatrigine must differentiate from Xcopri and XEN1101 in a highly competitive focal epilepsy market. |
seekingalpha.com |
2025-03-04 01:03:52 |
Czytaj oryginał (ang.) |
| Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates |
Praxis Precision Medicines, Inc. (PRAX) came out with a quarterly loss of $2.94 per share versus the Zacks Consensus Estimate of a loss of $2.96. This compares to loss of $2.97 per share a year ago. |
zacks.com |
2025-02-28 12:10:23 |
Czytaj oryginał (ang.) |
| Praxis Precision Medicines Provides Update on Essential3 and Corporate Update |
BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided an update on the interim analysis for Study 1 of the Essential3 program of ulixacaltamide in essential tremor (ET), an update on other therapies in development and a financial update. |
globenewswire.com |
2025-02-28 10:00:00 |
Czytaj oryginał (ang.) |
| Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release |
Praxis Precision Medicines (PRAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-25 13:00:32 |
Czytaj oryginał (ang.) |
| Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on February 3, 2025, the Compensation Committee of Praxis' Board of Directors granted non-qualified stock option awards to purchase an aggregate of 4,050 shares of its common stock and restricted stock unit awards covering an aggregate of 3,038 shares of its common stock to three new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The stock options and restricted stock units were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-02-04 19:00:00 |
Czytaj oryginał (ang.) |
| Praxis Precision Medicines to Present at Two February Investor Conferences |
BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences: |
globenewswire.com |
2025-02-03 19:00:00 |
Czytaj oryginał (ang.) |
| Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities |
Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four commercial assets by 2028 |
globenewswire.com |
2025-01-12 23:00:00 |
Czytaj oryginał (ang.) |
| Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome |
Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those granted for SCN2A and SCN8A DEEs Praxis plans to initiate an all-DEE trial (EMERALD), inclusive of Dravet syndrome, in 1H2025 BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) for relutrigine in Dravet syndrome. “We are thrilled to have been granted rare pediatric disease designation for relutrigine in Dravet syndrome. |
globenewswire.com |
2024-12-18 10:00:00 |
Czytaj oryginał (ang.) |
| Praxis Precision Medicines to Present at Upcoming December Investor Conferences |
BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences in December 2024. |
globenewswire.com |
2024-12-03 10:00:00 |
Czytaj oryginał (ang.) |
| Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences |
BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be participating in three upcoming investor conferences in November 2024. |
globenewswire.com |
2024-11-06 19:00:00 |
Czytaj oryginał (ang.) |
| Praxis Precision Medicines, Inc. (PRAX) Q3 2024 Earnings Call Transcript |
Praxis Precision Medicines, Inc. (NASDAQ:PRAX ) Q3 2024 Earnings Conference Call November 6, 2024 8:00 AM ET Company Participants Dan Ferry - IR, LifeSci Communications Marcio Souza - President & CEO Tim Kelly - CFO Conference Call Participants Ritu Baral - TD Cowen Yasmeen Rahimi - Piper Sandler Joon Lee - Truist Securities Francois Brisebois - Oppenheimer Yatin Suneja - Guggenheim Douglas Tsao - H.C. Wainwright Kambiz Yazdi - Jefferies Ami Fadia - Needham Joel Beatty - Baird Laura Chico - Wedbush Securities Operator Good day and thank you for standing by. |
seekingalpha.com |
2024-11-06 13:56:51 |
Czytaj oryginał (ang.) |
| Praxis Precision Medicines, Inc. (PRAX) Reports Q3 Loss, Misses Revenue Estimates |
Praxis Precision Medicines, Inc. (PRAX) came out with a quarterly loss of $2.75 per share versus the Zacks Consensus Estimate of a loss of $2.01. This compares to loss of $2.70 per share a year ago. |
zacks.com |
2024-11-06 11:46:09 |
Czytaj oryginał (ang.) |
| Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results |
Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing anticipated in 2025 |
globenewswire.com |
2024-11-06 09:30:00 |
Czytaj oryginał (ang.) |
| Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024 |
BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced it will report its financial results from the third quarter ended September 30, 2024, before the financial markets open on Wednesday, November 6, 2024. |
globenewswire.com |
2024-11-01 10:00:00 |
Czytaj oryginał (ang.) |
| Praxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last? |
Praxis Precision Medicines (PRAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2024-10-04 14:05:27 |
Czytaj oryginał (ang.) |
| Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures |
Shares of PRAX gains on positive efficacy data from the mid-stage study of its investigational candidate, relutrigine, for two epilepsy indications. |
zacks.com |
2024-09-04 15:36:18 |
Czytaj oryginał (ang.) |
| Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations |
BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that that it will present preclinical and clinical data from three of its epilepsy programs at the International League Against Epilepsy (ILAE) 15th European Epilepsy Congress (EEC), being held from September 7 to 11, 2024 in Rome, Italy. |
globenewswire.com |
2024-09-04 12:00:00 |
Czytaj oryginał (ang.) |
| Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine |
Placebo-adjusted monthly motor seizure reduction of 46% during double-blind period Over 30% of patients achieved seizure freedom status while on relutrigine Meaningful gains observed in alertness, communication and seizure severity 75% reduction in median seizure rate seen for patients in the long-term extension Registrational phase of the EMBOLD study for SCN2A and 8A initiated BOSTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today shared positive topline results for its Phase 2, proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients. |
globenewswire.com |
2024-09-03 11:30:00 |
Czytaj oryginał (ang.) |
| Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024 |
BOSTON, Mass., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will share the topline results from the Phase 2 EMBOLD study of relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies (DEEs) on Tuesday, September 3, 2024, prior to market open. Following the announcement, the Company will host a conference call and webcast presentation at 8:00 a.m. ET to discuss the trial results. |
globenewswire.com |
2024-09-02 21:00:00 |
Czytaj oryginał (ang.) |
| Praxis Precision Medicines (PRAX) Upgraded to Buy: What Does It Mean for the Stock? |
Praxis Precision Medicines (PRAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-08-15 17:06:10 |
Czytaj oryginał (ang.) |
| Praxis Precision Medicines, Inc. (PRAX) Q2 2024 Earnings and Corporate Update Call Transcript |
Praxis Precision Medicines, Inc. (NASDAQ:PRAX ) Q2 2024 Earnings Conference Call August 13, 2024 8:00 AM ET Company Participants Marcio Souza - President and Chief Executive Officer Tim Kelly - Chief Financial Officer Daniel Ferry - Investor Relations, Life Science Advisors Conference Call Participants Yasmeen Rahimi - Piper Sandler Joon Lee - Truist Securities Francois Brisebois - Oppenheimer Yatin Suneja - Guggenheim Ritu Baral - TD Cowan Joel Beatty - Baird Ami Fadia - Needham Douglas Tsao - HC Wainwright & Co Kambiz Yazdi - Jeffries Operator Good day, thank you for standing by. Welcome to the Praxis Precision Medicines' Second Quarter 2024 Corporate Update Conference Call. |
seekingalpha.com |
2024-08-13 18:47:09 |
Czytaj oryginał (ang.) |
| Praxis Precision Medicines, Inc. (PRAX) Reports Q2 Loss, Lags Revenue Estimates |
Praxis Precision Medicines, Inc. (PRAX) came out with a quarterly loss of $1.74 per share versus the Zacks Consensus Estimate of a loss of $2.38. This compares to loss of $7.35 per share a year ago. |
zacks.com |
2024-08-13 13:20:38 |
Czytaj oryginał (ang.) |
| Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024 |
BOSTON, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced it will report its financial results from the second quarter ended June 30, 2024, before the financial markets open on Tuesday, August 13, 2024. |
globenewswire.com |
2024-08-05 20:01:00 |
Czytaj oryginał (ang.) |
| Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains? |
Praxis Precision Medicines (PRAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2024-06-21 08:35:27 |
Czytaj oryginał (ang.) |
| Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOSTON, June 04, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on June 3, 2024, the Compensation Committee of Praxis' Board of Directors granted non-qualified stock option awards to purchase an aggregate of 300 shares of its common stock and restricted stock unit awards covering an aggregate of 225 shares of its common stock to one new non-executive employee under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the “2024 Inducement Plan”). The stock options and restricted stock units were granted as inducements material to the employee's entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-06-04 21:00:00 |
Czytaj oryginał (ang.) |
| Praxis Precision Medicines to Participate in Upcoming Investor Conferences |
BOSTON, May 17, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be participating in three upcoming conferences. |
globenewswire.com |
2024-05-17 12:00:00 |
Czytaj oryginał (ang.) |
| Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results |
Plans to initiate two efficacy studies investigating PRAX-628 in focal onset seizures in the second half of 2024 and first half of 2025, respectively |
globenewswire.com |
2024-05-13 11:00:00 |
Czytaj oryginał (ang.) |